Table 3.
Cox’s proportional hazards model for predictors of overall survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age ≥65 y/o (vs. <65 y/o) | 0.664 | 0.299-1.473 | 0.314 | |||
| Male (vs. female) | 1.313 | 0.460-3.745 | 0.610 | |||
| ECOG 0 (vs. 1/2) | 0.449 | 0.202-1.007 | 0.059 | |||
| Viral infection (vs. others) | 0.669 | 0.257-1.742 | 0.411 | |||
| Child-Pugh grade A (vs. B) | 0.518 | 0.223-1.206 | 0.127 | |||
| ALBI grade I (vs. II/III) | 0.521 | 0.236-0.750 | 0.047 | 0.942 | 0.294-3.016 | 0.920 |
| Portal vein thrombosis (vs. No) | 2.365 | 1.160-4.825 | 0.018 | 1.397 | 0.455-4.286 | 0.559 |
| Extrahepatic metastasis (vs. No) | 1.114 | 0.558-2.225 | 0.759 | |||
| AFP≥400 ng/ml (vs. <400 ng/ml) | 1.445 | 0.724-2.886 | 0.296 | |||
| BCLC stage B (vs. C) | 0.474 | 0.195-1.151 | 0.099 | |||
| Beyond up-to-7 criteria (vs. within) | 1.082 | 0.417-2.808 | 0.872 | |||
| First line (vs. second line or later) | 1.454 | 0.725-2.917 | 0.292 | |||
| CRAFITY score low (vs. high) | 0.144 | 0.046-0.454 | 0.001 | 0.143 | 0.042-0.481 | 0.002 |
| ≥75% AFP decrease or ≤10% AFP increase at 6 weeks (vs. No) | 0.633 | 0.309-0.896 | 0.033 | 0.337 | 0.108-0.850 | 0.031 |
| Prior loco-regional therapy (vs. No) | 0.525 | 0.263-1.047 | 0.067 | |||
| IrAE (vs. No) | 1.184 | 0.560-2.505 | 0.659 | |||
Abbreviations: AFP, Alpha-fetoprotein; ALBI, Albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; CRAFITY, CRP and AFP in Immunotherapy; ECOG, Eastern Cooperative Oncology Group; IrAE, Immunotherapy related adverse events.